Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Stocks News & Analysis
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
stocks
The 10 best US dividend shares
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,626.20 | 52.80 | 0.62% |
| CAC 40 | 7,942.42 | 58.79 | 0.75% |
| DAX 40 | 24,036.11 | 101.13 | 0.42% |
| Dow JONES (US) | 42,677.24 | 114.83 | -0.27% |
| FTSE 100 | 8,781.12 | 81.81 | 0.94% |
| HKSE | 23,792.11 | 110.63 | 0.47% |
| NASDAQ | 19,142.71 | 72.75 | -0.38% |
| Nikkei 225 | 37,454.14 | 75.35 | -0.20% |
| NZX 50 Index | 12,699.61 | 55.38 | 0.44% |
| S&P 500 | 5,940.46 | 23.14 | -0.39% |
| S&P/ASX 200 | 8,401.90 | 58.60 | 0.70% |
| SSE Composite Index | 3,393.49 | 13.02 | 0.39% |